NVO - FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts | Benzinga
Following a preliminary review, the U.S. Food and Drug Administration found no evidence that weight-loss drugs cause suicidal thoughts.
What To Know: Following reports of suicidal thoughts or actions, the FDA conducted a review of a class of popular weight-loss and diabetes drugs known as GLP-1 RAs, which includes Novo Nordisk's (NYSE:NVO) Wegovy and Ozempic and Eli Lilly and Company's (NYSE:LLY) Zepbound.
The FDA released an update on Thursday stating that its preliminary review did not show definitive evidence that the drugs cause ...